{
  "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
  "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 25,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "Includes specific study references and definitions for abbreviations like GPR119, MASH, and GLP-1.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/11",
  "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
  "deckJsonHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7.json",
  "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.5,
        "x": 0.45,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Change in Plasma Inflammatory Cytokine & Chemokines",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56900306-35f9-44ef-87e0-46100c17d126",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Change in Hepatic Immune Cell Infiltration",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf0ab88d-728d-405e-afd7-73a866fa583f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Notes: GPR119 (G Protein-Coupled Receptor 119); MASH (Non-Alcoholic Steatohepatitis); GLP-1 (Glucagon-Like Peptide 1); DA-1241 (L), 30 mg/kg/day; DA-1241 (H), 100 mg/kg/day; Elafibranor (PPARα/δ agonist with anti-inflammatory effects; discontinued in Phase 3 for MASH); Sitagliptin (JANUVIA™, approved DPP4 inhibitor for T2DM)\n1. Dong-A Study Report 103420\n2. Dong-A Study Report 104458\n3. Park H et al. 80th Scientific Session of American Diabetes Association, 2020, Poster presentation 216-LB",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36ae2223-577a-4d23-b2ff-830edb334809",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "DA-1241 was shown to improve BOTH hepatic and systemic inflammation effectively\nCo-administered with a DDD4 potentiated the anti-inflammatory effect",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8fedc97-779d-4a9d-a951-d4afb2c62a4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "DA-1241: Differentiated Anti-Inflammatory Effect in MASH Mice (1-3)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23058fc3-7fe4-48bf-b038-91edf6cfc81a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "25860635-9a8f-4833-ad7c-e59ee8184cb7",
      "evidence": "Multiple list/bullet components presenting information in a structured format",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "fc2a383c-968e-4c6a-836f-347c2e1bb09a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-14 detail the solution, including DA-1241 and its competitive differentiation",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
      "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
      "position": 1,
      "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}